Daiwa Securities Group Inc. Acquires 9,364 Shares of Zai Lab Limited (NASDAQ:ZLAB)

Daiwa Securities Group Inc. lifted its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB) by 4,851.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,557 shares of the company’s stock after purchasing an additional 9,364 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Zai Lab were worth $231,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Zai Lab by 58.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,559 shares of the company’s stock worth $231,000 after purchasing an additional 3,514 shares during the period. Swedbank AB acquired a new stake in shares of Zai Lab during the 1st quarter worth approximately $244,000. Dimensional Fund Advisors LP bought a new position in Zai Lab in the second quarter valued at approximately $270,000. Tidal Investments LLC acquired a new position in Zai Lab during the first quarter valued at approximately $334,000. Finally, Renaissance Technologies LLC lifted its stake in Zai Lab by 91.9% during the second quarter. Renaissance Technologies LLC now owns 28,214 shares of the company’s stock worth $489,000 after purchasing an additional 13,514 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Price Performance

Shares of ZLAB opened at $28.85 on Monday. The business has a 50-day moving average of $27.30 and a 200-day moving average of $21.71. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -10.42 and a beta of 1.04. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $36.60.

Analyst Ratings Changes

Several analysts recently weighed in on ZLAB shares. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their price objective on Zai Lab from $38.00 to $44.00 and gave the company an “overweight” rating in a report on Monday, October 21st.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.